You are here

Arena Pharmaceuticals

Arena’s Comeback Continues with $800M Deal for Blood Disease Drug

Arena’s Comeback Continues with $800M Deal for Blood Disease Drug

Xconomy

Arena Pharmaceuticals

United Therapeutics

Flag link:

Arena 3 for 3 as Crohn’s drug meets proof-of-concept test

Arena 3 for 3 as Crohn’s drug meets proof-of-concept test

Fierce Biotech

Arena Pharmaceuticals

Crohn's Disease

Flag link:

3 Biotech Stocks That Skyrocketed This Week

3 Biotech Stocks That Skyrocketed This Week

Motley Fool

Arena Pharmaceuticals

Heron Therapeutics

Flag link:

Arena Pharmaceuticals Takes Aim at Celgene

Arena Pharmaceuticals Takes Aim at Celgene

Motley Fool

Arena Pharmaceuticals

ulcerative colitis

Flag link:

Here's Why Arena Pharmaceuticals, Inc. Surged Again on Wednesday

Here's Why Arena Pharmaceuticals, Inc. Surged Again on Wednesday

Motley Fool

Arena Pharmaceuticals

ulcerative colitis

Flag link:

Celgene's Future Growth Could Depend on a Competitor's Trial This Quarter

Celgene's Future Growth Could Depend on a Competitor's Trial This Quarter

Motley Fool

Arena Pharmaceuticals

multiple sclerois

Flag link:

Three Interviews From the J.P. Morgan Healthcare Conference

Three Interviews From the J.P. Morgan Healthcare Conference

Motley Fool

Arena Pharmaceuticals

Spark Therapeutics

Flag link:

Here's What Lifted Arena Pharmaceuticals, Inc. Stock in September

Here's What Lifted Arena Pharmaceuticals, Inc. Stock in September

Motley Fool

Arena Pharmaceuticals

pulmonary arterial hypertension

Flag link:

Arena Pharma Skyrockets on Heart Disease Data, Stock Could Still Double -Firm Says

Arena Pharma Skyrockets on Heart Disease Data, Stock Could Still Double -Firm Says

TheStreet.com

Arena Pharmaceuticals

pulmonary arterial hypertension

Flag link:

Arena takes a big step down the comeback trail with PhII success, shares rocket up

Arena takes a big step down the comeback trail with PhII success, shares rocket up

Endpoints

Arena Pharmaceuticals

clinical trials

pulmonary arterial hypertension

Flag link:

Here's Why Arena Pharmaceuticals Rose as Much as 18.3% Friday

Here's Why Arena Pharmaceuticals Rose as Much as 18.3% Friday

Motley Fool

Arena Pharmaceuticals

Flag link:

Arena Pharmaceuticals beats 4Q profit forecasts

Arena Pharmaceuticals beats 4Q profit forecasts

Yahoo/AP

Arena Pharmaceuticals

Flag link:

Arena Turns Page On Belviq - Restructures Deal With Eisai

Arena Turns Page On Belviq - Restructures Deal With Eisai

Seeking Alpha

Arena Pharmaceuticals

Flag link:

Arena Pharmaceuticals reports 3Q loss

Arena Pharmaceuticals reports 3Q loss

Yahoo/AP

Arena Pharmaceuticals

Flag link:

Drug maker faces a shareholder suit for failing to tell the whole truth

Drug maker faces a shareholder suit for failing to tell the whole truth

Stat/Pharmalot

Arena Pharmaceuticals

Flag link:

Eisai Inc. and Arena Pharmaceuticals Announce Availability of Once-Daily BELVIQ XR® (lorcaserin HCl) Extended-Release Tablets

Eisai Inc. and Arena Pharmaceuticals Announce Availability of Once-Daily BELVIQ XR® (lorcaserin HCl) Extended-Release Tablets

Yahoo

Arena Pharmaceuticals

Flag link:

Arena Launches Drug Discovery Incubator (ARNA)

Arena Launches Drug Discovery Incubator (ARNA)

Investopedia

Arena Pharmaceuticals

Beacon Discovery

Flag link:

Arena to focus on R&D with new spinout and old candidates

Arena to focus on R&D with new spinout and old candidates

Fierce Biotech

Arena Pharmaceuticals

Beacon Discovery

Flag link:

Arena Pharma stock rises 8.8% after weight-loss drug is approved

Arena Pharma stock rises 8.8% after weight-loss drug is approved

Marketwatch

Arena Pharmaceuticals

Flag link:

Arena - Anti-Obesity Drug Lorcaserin Approved In Mexico

Arena - Anti-Obesity Drug Lorcaserin Approved In Mexico

Seeking Alpha

Arena Pharmaceuticals

Flag link:

Pages